CY1108713T1 - Συντηγμενες ενωσεις προς αναστολη του υποδοχεα βανιλλοϊδους υποτυπου 1 (vr1) - Google Patents

Συντηγμενες ενωσεις προς αναστολη του υποδοχεα βανιλλοϊδους υποτυπου 1 (vr1)

Info

Publication number
CY1108713T1
CY1108713T1 CY20091100044T CY091100044T CY1108713T1 CY 1108713 T1 CY1108713 T1 CY 1108713T1 CY 20091100044 T CY20091100044 T CY 20091100044T CY 091100044 T CY091100044 T CY 091100044T CY 1108713 T1 CY1108713 T1 CY 1108713T1
Authority
CY
Cyprus
Prior art keywords
van1
suspend
compounds
fused compounds
subunit receptor
Prior art date
Application number
CY20091100044T
Other languages
Greek (el)
English (en)
Inventor
Arthur Gomtsyan
Erol K Bayburt
Chih-Hung Lee
John R Koenig
Robert Schmidt
Kirill Lukin
Gilles Chambournier
Margaret Hsu
M Robert Leanna
Russel D Cink
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33555102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1108713(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/459,925 external-priority patent/US7015233B2/en
Priority claimed from US10/864,068 external-priority patent/US7375126B2/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CY1108713T1 publication Critical patent/CY1108713T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Materials For Photolithography (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CY20091100044T 2003-06-12 2009-01-14 Συντηγμενες ενωσεις προς αναστολη του υποδοχεα βανιλλοϊδους υποτυπου 1 (vr1) CY1108713T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/459,925 US7015233B2 (en) 2003-06-12 2003-06-12 Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
US10/864,068 US7375126B2 (en) 2003-06-12 2004-06-09 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
EP04754996A EP1658269B1 (en) 2003-06-12 2004-06-10 Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor

Publications (1)

Publication Number Publication Date
CY1108713T1 true CY1108713T1 (el) 2014-04-09

Family

ID=33555102

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20091100044T CY1108713T1 (el) 2003-06-12 2009-01-14 Συντηγμενες ενωσεις προς αναστολη του υποδοχεα βανιλλοϊδους υποτυπου 1 (vr1)
CY20111100738T CY1111945T1 (el) 2003-06-12 2011-07-28 Συντηγμενες ενωσεις προς αναστολη του υποδοχεα βανιλλοειδους υποτυπου 1 (vr1)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20111100738T CY1111945T1 (el) 2003-06-12 2011-07-28 Συντηγμενες ενωσεις προς αναστολη του υποδοχεα βανιλλοειδους υποτυπου 1 (vr1)

Country Status (20)

Country Link
EP (2) EP2017265B1 (enExample)
JP (2) JP4857113B2 (enExample)
KR (2) KR101138216B1 (enExample)
CN (1) CN102617464A (enExample)
AT (2) ATE411982T1 (enExample)
AU (2) AU2004247721C1 (enExample)
BR (1) BRPI0411116A (enExample)
CA (2) CA2756058A1 (enExample)
CY (2) CY1108713T1 (enExample)
DE (1) DE602004017329D1 (enExample)
DK (2) DK2017265T3 (enExample)
ES (1) ES2318308T3 (enExample)
IL (4) IL172457A (enExample)
MX (1) MXPA05013550A (enExample)
NZ (3) NZ590234A (enExample)
PL (2) PL2017265T3 (enExample)
PT (2) PT1658269E (enExample)
SI (2) SI2017265T1 (enExample)
TW (3) TWI366461B (enExample)
WO (1) WO2004111009A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089296A2 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
WO2006045119A2 (en) 2004-10-20 2006-04-27 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
WO2006062982A2 (en) 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Urea inhibitors of map kinases
US7612200B2 (en) 2004-12-07 2009-11-03 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
EP1931681B1 (en) 2005-10-07 2012-11-14 Glenmark Pharmaceuticals S.A. Substituted benzofused derivatives and their use as vanilloid receptor ligands
CA2626579A1 (en) * 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
AU2006306146A1 (en) * 2005-10-28 2007-05-03 Abbott Laboratories Indazole derivatives that inhibit TRPV1 receptor
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
AU2007238071B2 (en) * 2006-04-18 2012-06-07 Abbvie Inc. Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof
WO2009081222A1 (en) 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands
WO2009096701A2 (en) 2008-01-28 2009-08-06 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
JP5438103B2 (ja) 2008-07-02 2014-03-12 アモーレパシフィック コーポレイション バニロイド受容体アンタゴニストとしての新規化合物、その異性体またはその薬学的に許容される塩、並びにそれを含む医薬組成物
UY32180A (es) * 2008-10-17 2010-05-31 Abbott Lab Antagonistas del receptor transitorio potencial de vanilloides 1 (trpv1)
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
NZ618795A (en) 2011-05-13 2015-07-31 Array Biopharma Inc Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
BR112014027644A2 (pt) * 2012-05-09 2017-06-27 Bayer Cropscience Ag 5-halogenopirazol-indanil-carboxamidas
ME02990B (me) 2012-11-13 2018-10-20 Array Biopharma Inc Jedinjenja n-pirolidinil, n'-pirazolil- uree, tiouree, guanidina i cijanoguanidina kао inhibitori trka kinaze
CA2891334C (en) 2012-11-13 2021-10-19 Array Biopharma Inc. Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078417A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
CN106459013B (zh) 2014-05-15 2019-10-25 阵列生物制药公司 作为trka激酶抑制剂的化合物及其用途
CA3022432A1 (en) * 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Sigma receptor binders
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW536734B (en) * 2000-07-31 2003-06-11 Clariant Int Ltd Process for manufacturing a microelectronic device
JP2005501873A (ja) * 2001-07-31 2005-01-20 バイエル・ヘルスケア・アクチェンゲゼルシャフト アミン誘導体
JP2003192587A (ja) * 2001-12-26 2003-07-09 Bayer Ag 尿素誘導体
DE60325834D1 (de) * 2002-02-20 2009-03-05 Abbott Lab Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
GB0206876D0 (en) * 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
AU2003241453A1 (en) * 2002-05-17 2003-12-02 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor

Also Published As

Publication number Publication date
TWI366461B (en) 2012-06-21
PL1658269T3 (pl) 2009-08-31
IL172457A (en) 2011-12-29
CN102617464A (zh) 2012-08-01
CA2756058A1 (en) 2004-12-23
ATE510824T1 (de) 2011-06-15
MXPA05013550A (es) 2006-04-05
AU2010257277A1 (en) 2011-01-13
JP2011153148A (ja) 2011-08-11
BRPI0411116A (pt) 2006-07-18
PT2017265E (pt) 2011-07-29
AU2004247721C1 (en) 2011-12-22
TW200509926A (en) 2005-03-16
PT1658269E (pt) 2009-01-09
PL2017265T3 (pl) 2011-11-30
IL215997A0 (en) 2011-12-29
IL172457A0 (en) 2006-04-10
KR101138216B1 (ko) 2012-09-05
JP2007500753A (ja) 2007-01-18
TW201300361A (zh) 2013-01-01
KR20110089464A (ko) 2011-08-08
CY1111945T1 (el) 2015-11-04
IL216046A0 (en) 2011-12-29
IL207335A0 (en) 2010-12-30
NZ543713A (en) 2009-08-28
HK1126488A1 (en) 2009-09-04
ATE411982T1 (de) 2008-11-15
TW201038269A (en) 2010-11-01
SI1658269T1 (sl) 2009-04-30
EP2017265A1 (en) 2009-01-21
TWI394569B (zh) 2013-05-01
AU2004247721B2 (en) 2011-01-20
EP1658269B1 (en) 2008-10-22
HK1093727A1 (en) 2007-03-09
JP4857113B2 (ja) 2012-01-18
KR101150324B1 (ko) 2012-06-13
KR20060058769A (ko) 2006-05-30
SI2017265T1 (sl) 2011-09-30
NZ578264A (en) 2011-02-25
WO2004111009A1 (en) 2004-12-23
AU2010257277B2 (en) 2011-08-18
NZ590234A (en) 2012-07-27
DE602004017329D1 (de) 2008-12-04
DK1658269T3 (da) 2009-01-12
DK2017265T3 (da) 2011-09-19
CA2526872C (en) 2013-02-05
EP1658269A1 (en) 2006-05-24
AU2004247721A1 (en) 2004-12-23
IL207335A (en) 2012-02-29
EP2017265B1 (en) 2011-05-25
CA2526872A1 (en) 2004-12-23
ES2318308T3 (es) 2009-05-01

Similar Documents

Publication Publication Date Title
CY1111945T1 (el) Συντηγμενες ενωσεις προς αναστολη του υποδοχεα βανιλλοειδους υποτυπου 1 (vr1)
IL173269A0 (en) Compounds for inflammation and immune-related uses
TW200621232A (en) Compounds for inflammation and immune-related uses
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
IL216455A0 (en) Heterocyclic inhibitors of mek and methods of use thereof
WO2004013120A8 (en) Novel benzodioxoles
WO2006062981A3 (en) Antagonists to the vanilloid receptor subtype 1 (vr1) and uses thereof
MEP61208A (bs) Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavistan od natrijuma
SE0302487D0 (sv) Novel compounds
WO2004020431A3 (en) Novel benzoimidazole derivatives useful as antiproliferative agents
MY142018A (en) Thiophene derivatives as chk 1 inihibitors
WO2005092895A3 (en) Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
MXPA04006031A (es) Compuestos para el tratamiento de trastornos inflamatorios.
SI0773943T1 (en) Compounds useful as antiproliferative agents and garft inhibitors
WO2006113552A8 (en) Cyanoarylamines
PT1202959E (pt) Aminobenzofenonas como inibidores de il-1-beta e tnf-alfa
WO2005040121A3 (en) Amides that inhibit vanilloid receptor subtype 1 (vr1) receptor
MX2007007100A (es) Benzisotiazol-1,1-dioxido que actua como antagonistas para el subtipo 1 del receptor de vanilloida (vr1) y usos de los mismos.
MXPA04005988A (es) 3,4-dihidro-1h-isoquinolin-2-il-derivados.
WO2006029210A3 (en) Acyclic 1,3-diamines and uses therefor
DK1072601T3 (da) 4-Arylpiperidinderivater til behandling af pruritus
MX2008002073A (es) Compuestos para el tratamiento de trastornos inflamatorios.
GEP20084394B (en) Novel intermediate for the preparation of therapeutically active imidazopyridines